Author/Authors :
Ochi، Mohammad Mahdi نويسنده Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran , , Amoabediny، Ghasem نويسنده , , Rezayat Sorkhabadi، Seyed Mahdi نويسنده Department of Pharmacology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran , , Akbarzadeh، Azim نويسنده Pasteur Institute of Iran (IPI), Tehran, Iran , , Ebrahimi، Bahman نويسنده Biotechnology Group, Department of Chemical Engineering, Faculty of Engineering, Tarbiat Modares University, P.O. Box 14115-143, Tehran, I.R. Iran ,
Abstract :
Objective: This study aimed to evaluate a co-encapsulated pegylated nano-liposome
system based on two herbal anti-tumor drugs, silibinin and glycyrrhizic acid, for delivery
to a hepatocellular carcinoma (HCC) cell line (HepG2).
Materials and Methods: In this experimental study, co-encapsulated nano-liposomes
by the thin layer film hydration method with HEPES buffer and sonication at 60% amplitude.
Liposomes that co-encapsulated silibinin and glycyrrhizic acid were prepared
with a specified molar ratio of dipalmitoylphosphatidylcholine (DPPC), cholesterol
(CHOL), and methoxy-polyethylene glycol 2000 (PEG2000)–derived distearoyl phosphatidylethanolamine
(mPEG2000-DSPE). We used the MTT technique to assess cytotoxicity
for various concentrations of co-encapsulated nano-liposomes, free silibinin
(25% w/v) and glycyrrhizic acid (75% w/v) on HepG2 and fibroblast cell lines over a
48-hour period.
Results: Formulation of pegylated nano-liposomes showed a narrow size distribution
with an average diameter of 46.3 nm. The encapsulation efficiency (EE) for silibinin was
24.37%, whereas for glycyrrhizic acid it was 68.78%. Results of in vitro cytotoxicity showed
significantly greater co-encapsulated nano-liposomes on the HepG2 cell line compared to
the fibroblast cell line. The half maximal inhibitory concentration (IC50) for co-encapsulated
pegylated nanoliposomal herbal drugs was 48.68 ?g/ml and free silibinin with glycyrrhizic
acid was 485.45 ?g/ml on the HepG2 cell line.
Conclusion: This in vitro study showed that nano-liposome encapsulation of silibinin with
glycyrrhizic acid increased the biological activity of free drugs, increased the stability of
silibinin, and synergized the therapeutic effect of silibinin with glycyrrhizic acid. The IC50 of
the co-encapsulated nano-liposomes was lower than the combination of free silibinin and
glycyrrhizic acid on the HepG2 cell line.
